keyword
https://read.qxmd.com/read/38697184/setmelanotide-for-the-treatment-of-acquired-hypothalamic-obesity-a-phase-2-open-label-multicentre-trial
#1
JOURNAL ARTICLE
Christian L Roth, Cecilia Scimia, Ashley H Shoemaker, Michael Gottschalk, Jennifer Miller, Guojun Yuan, Sonali Malhotra, M Jennifer Abuzzahab
BACKGROUND: Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. METHODS: This phase 2, open-label, multicentre trial was done in five centres in the USA. Eligible patients were aged between 6 and 40 years with obesity and history of hypothalamic injury or diagnosis of a non-malignant tumour affecting the hypothalamus that was treated with surgery, chemotherapy, or radiation...
April 29, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38687927/hepatic-artery-infusion-chemotherapy-with-systemic-capecitabine-and-camrelizumab-for-treating-unresectable-hilar-cholangiocarcinoma-an-initial-investigation-of-efficacy-and-safety
#2
JOURNAL ARTICLE
Long Li, Song Liu, Qingdong Wang, Yanhua Wang, Guangji Yu
OBJECTIVE: This study aimed to evaluate the efficacy and safety of sequential treatment of continuous transcatheter hepatic artery infusion chemotherapy (HAIC) with systemic capecitabine monotherapy and camrelizumab for treating unresectable hilar cholangiocarcinoma (HCCA). METHODS: This study retrospectively analyzed patients with unresectable HCCA admitted to Linyi Cancer Hospital in Shandong Province from October 2019 to December 2021. All enrolled patients were treated with HAIC (mFOLFOX7) + camrelizumab for 2-6 cycles and administered systemic therapy with capecitabine and camrelizumab...
April 1, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38685589/tomotherapy-in-synchronous-and-metachronous-bilateral-breast-cancer-clinical-experience
#3
JOURNAL ARTICLE
Yernar Orda, Tanzhas Shayakhmetov, Saniya Baiturova, Daulet Berikbol, Rauan Otynshiyev, Aigul Brimova, Bolat Saktashev, Ainur Baisalbayeva, Ainur Samigatova
PURPOSE OF STUDY: The objective of this research is to present our firsthand experience and provide up-to-date data for the further study of cases involving simultaneous breast irradiation using helical Tomotherapy, ©Accuray Inc. METHODS: The radical treatment options for bilateral breast cancer are surgery, chemotherapy, and radiation therapy. Being that radiotherapy for bilateral breast cancer is challenging due to limitations in the geometry of modern radiotherapy equipment, helical Tomotherapy was chosen as an appropriate technique of irradiation...
April 29, 2024: Journal of Applied Clinical Medical Physics
https://read.qxmd.com/read/38679715/mesenchymal-stromal-stem-cells-promote-intestinal-epithelium-regeneration-after-chemotherapy-induced-damage
#4
JOURNAL ARTICLE
B Yetkin-Arik, S A Jansen, S Varderidou-Minasian, B Westendorp, K-P Skarp, M Altelaar, C A Lindemans, M J Lorenowicz
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for leukemia and a range of non-malignant disorders. The success of the therapy is hampered by occurrence of acute graft-versus-host disease (aGvHD); an inflammatory response damaging recipient organs, with gut, liver, and skin being the most susceptible. Intestinal GvHD injury is often a life-threatening complication in patients unresponsive to steroid treatment. Allogeneic mesenchymal stromal/stem cell (MSC) infusions are a promising potential treatment for steroid-resistant aGvHD...
April 29, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38669609/curing-stage-iv-melanoma-where-have-we-been-and-where-are-we
#5
REVIEW
Pui Ying Chan, Pippa G Corrie
Little more than 10 years ago, metastatic melanoma was considered to have one of the poorest cancer outcomes, associated with a median overall survival of 6-8 months. Cytotoxic chemotherapy offered modest response rates of 20%-30%, but no clear survival benefit. Patients were routinely enrolled in clinical trials as their first-line therapy in the search for effective novel therapeutics. Remarkable developments in molecular biology, cancer genomics, immunology, and drug discovery have dominated the early part of the 21st century, and nowhere have the benefits been better realized than in the transformation of outcomes for patients with metastatic melanoma: since 2011, 14 new agents have been approved that significantly increase survival, with long-term remissions and, possibly now, potential for cure...
June 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38660850/-effect-of-low-dose-recombinant-interleukin-2-therapy-on-immunocyte-subsets-in-children-with-solid-tumor
#6
JOURNAL ARTICLE
Jia-Ying Lei, Yang Li, Chun-Mou Li, Xi-Lin Xiong, Chu-Chu Feng, Wen-Jun Weng, Xiao-Min Peng, Dun-Hua Zhou, Ke Huang
OBJECTIVE: To evaluate the effect of low-dose recombinant interleukin-2 (rIL-2) therapy on immunocyte subsets and its side effects in children with solid tumor. METHODS: A total of 22 children (11 males and 11 females) with solid tumor in our department from December 2012 to November 2017 were selected, with a median age of 9 (3-16) years old when starting IL-2 therapy. ALL surgeries and chemotherapy of children had been completed before low-dose rIL-2 therapy, and 17 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR)...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38657999/photobiomodulation-in-the-treatment-of-palmar-plantar-erythrodysesthesia-a-randomised-controlled-clinical-study-protocol
#7
JOURNAL ARTICLE
Valentina Lestido, Florencia Rodríguez, Agustín Rodríguez, Valeria Pombo, Romina Barrios, Christiane Pavani
INTRODUCTION: Hand-foot syndrome, also known as palmar-plantar erythrodysesthesia (PPE), is a complication caused by chemotherapy. Clinically, it manifests as erythema and oedema on the palms of the hands and feet, dry and scaly skin, accompanied by a sensation of tightness and pain. Extreme cases have blisters and ulcerations that may require hospitalisation and/or pause in cancer treatment. It can also be accompanied by paraesthesia. Considering the characteristics, photobiomodulation (PBM) may reduce the PPE effects...
April 23, 2024: BMJ Open
https://read.qxmd.com/read/38647846/cytotoxicity-of-subcritical-water-extracts-obtained-from-byproducts-generated-at-commercial-pecan-shelling-operations-on-cancer-cells
#8
JOURNAL ARTICLE
Canan Sevimli Gur, Nurhan Turgut Dunford, Zinar Pinar Gumus
This study examined potential of the extracts obtained from the byproducts generated at commercial pecan nut-shelling operations in cancer treatment. The subcritical water extracts obtained from two varieties, Native and Pawnee, were analyzed for their phenolic contents and compositions. Effects of the extracts on viability and IC50 of the human cell lines representing a broad range of cancer types, cervical, lung, skin, breast, colon and prostate cancers, were investigated. Although the effect of the temperature on the phenolic contents and compositions of the extracts was not statistically significant, the influence of the variety was extensive...
July 28, 2023: Bioresources and Bioprocessing
https://read.qxmd.com/read/38643693/hyaluronic-acid-oleylamine-and-chitosan-oleic-acid-conjugate-based-hybrid-nanoparticle-delivery-via-dissolving-microneedles-for-enhanced-treatment-efficacy-in-localized-breast-cancer
#9
JOURNAL ARTICLE
Abhishek Jha, Manish Kumar, Pooja Goswami, Manjit Manjit, Kanchan Bharti, Biplob Koch, Brahmeshwar Mishra
Microneedle technology offers a minimally invasive treatment strategy to deliver chemotherapeutics to localized tumors. Amalgamating the surface functionalized nanoparticles with microneedle technology can potentially deliver drugs directly to tumors and subsequently target cancer cells via, overexpressed receptors on the cell surface, thereby enhancing the treatment efficacy while reducing side effects. Here, we report cetuximab anchored hyaluronic acid-oleylamine and chitosan-oleic acid-based hybrid nanoparticle (HA-OA/CS-OA NPT)-loaded dissolving microneedles (MN) for targeted delivery of cabazitaxel (CBT) in localized breast cancer tumor...
April 18, 2024: Biomater Adv
https://read.qxmd.com/read/38642149/preventive-effect-of-free-radical-scavenger-edaravone-lotion-on-cyclophosphamide-chemotherapy-induced-alopecia
#10
JOURNAL ARTICLE
Takumi Tsuji, Katsuaki Yoneda, Yu Igawa, Erika Minamino, Nodoka Otani, Yuya Yoshida, Takeyuki Kohno
PURPOSE: We investigated the inhibitory effect of edaravone (EDR) lotion on chemotherapy-induced alopecia (CIA) to improve the quality of life for patients with cancer. METHODS: Wistar rats were intraperitoneally injected with cyclophosphamide (CPA, 75 mg/kg) to induce CIA and divided into six groups: (1) Control; (2) EDR 0%; (3) EDR 0.3%; (4) EDR 3%. The TUNEL-positive area was examined histologically, and mRNA expression levels of the apoptosis-related factors, such as B-cell/CLL lymphoma 2 (Bcl-2), and Bcl-2-associated X protein (Bax), were determined...
April 20, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38635829/geraniol-and-citral-recent-developments-in-their-anticancer-credentials-opening-new-vistas-in-complementary-cancer-therapy
#11
REVIEW
Gauri Srivastava, Esha Mukherjee, Ruchika Mittal, Deepak Ganjewala
About 10 million people are diagnosed with cancer each year. Globally, it is the second leading cause of death after heart disease, and by 2035, the death toll could reach 14.6 million. Several drugs and treatments are available to treat cancer, but survival rates remain low. Many studies in recent years have shown that plant-derived monoterpenes, particularly geraniol and citral, are effective against various cancers, including breast, liver, melanoma, endometrial, colon, prostate, and skin cancers. This trend has opened new possibilities for the development of new therapeutics or adjuvants in the field of cancer therapy...
April 19, 2024: Zeitschrift Für Naturforschung. C, A Journal of Biosciences
https://read.qxmd.com/read/38628415/immune-checkpoint-monoclonal-antibody-related-adverse-effects-in-neuro-ophthalmology
#12
JOURNAL ARTICLE
May Ameri, Nagham Al-Zubidi, Andrew G Lee
Immunotherapy has renovated the field of oncology. Usually, cancer is treated by surgery, chemotherapy, and radiation. Immunotherapy is a promising treatment that harnesses the patient's own immune system to target cancer. Immune checkpoint inhibitors (ICIs) have proven to be a promising treatment avenue for managing cancer; however, their use had been associated with a unique spectrum of adverse side effects called immune-related adverse events (irAEs). As ICIs become increasingly relevant in cancer management, it is crucial to address these irAEs affecting various systems in the body, including the skin, liver, gastrointestinal tract, endocrine system, and the eye...
2024: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://read.qxmd.com/read/38627287/outcome-of-bleomycin-electrosclerotherapy-of-slow-flow-malformations-in-adults-and-children
#13
JOURNAL ARTICLE
Vanessa F Schmidt, Özlem Cangir, Lutz Meyer, Constantin Goldann, Susanne Hengst, Richard Brill, Susanne von der Heydt, Milton Waner, Daniel Puhr-Westerheide, Osman Öcal, Muzaffer Reha Ümütlü, Nabeel Mansour, Jan Rudolph, Alena Sint, Florian Obereisenbuchner, Beate Häberle, Jens Ricke, Max Seidensticker, Walter A Wohlgemuth, Moritz Wildgruber
OBJECTIVES: To evaluate the safety and clinical outcome of bleomycin electrosclerotherapy (BEST) for treating extracranial slow-flow malformations. METHODS: In this retrospective investigation of a multicenter cohort presenting symptomatic slow-flow malformations, patient records were analyzed with respect to procedural details and complications. A treatment-specific, patient-reported questionnaire was additionally evaluated, obtained 3-12 months after the last treatment, to assess the subjective outcomes, including mobility, aesthetic aspects, and pain, as well as the occurrence of postprocedural skin hyperpigmentation...
April 16, 2024: European Radiology
https://read.qxmd.com/read/38619253/evaluation-and-activity-of-new-porphyrin-peptide-cage-type-conjugates-for-the-photoinactivation-of-mycobacterium-abscessus
#14
JOURNAL ARTICLE
Matthéo Alcaraz, Sébastien Lyonnais, Chandramouli Ghosh, John Jairo Aguilera-Correa, Sébastien Richeter, Sébastien Ulrich, Laurent Kremer
Mycobacterium abscessus is increasingly recognized as an emerging opportunistic pathogen causing severe lung diseases and cutaneous infections. However, treatment of M. abscessus infections remains particularly challenging, largely due to intrinsic resistance to a wide panel of antimicrobial agents. New therapeutic alternatives are urgently needed. Herein, we show that, upon limited irradiation with a blue-light source, newly developed porphyrin-peptide cage-type photosensitizers exert a strong bactericidal activity against smooth and rough variants of M...
April 15, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38616861/dna-methylation-of-microrna-365-1-induces-apoptosis-of-hair-follicle-stem-cells-by-targeting-dap3
#15
JOURNAL ARTICLE
Xin Liu, Ruofan Xi, Xinran Du, Yi Wang, Linyan Cheng, Ge Yan, Jianyong Zhu, Te Liu, Fulun Li
BACKGROUND: DNA methylation is a crucial epigenetic alteration involved in diverse biological processes and diseases. Nevertheless, the precise role of DNA methylation in chemotherapeutic drug-induced alopecia remains unclear. This study examined the role and novel processes of DNA methylation in regulating of chemotherapeutic drug-induced alopecia. METHODS: A mouse model of cyclophosphamide (CTX)-induced alopecia was established. Hematoxylin-eosin staining and immunohistochemical staining for the Ki67 proportion and a mitochondrial membrane potential assay (JC-1) were performed to assess the structural integrity and proliferative efficiency of the hair follicle stem cells (HFSCs)...
September 2024: Non-Coding RNA Research
https://read.qxmd.com/read/38601287/short-term-efficacy-and-safety-of-neoadjuvant-pyrotinib-plus-taxanes-for-early-her2-positive-breast-cancer-a-single-arm-exploratory-phase-ii-trial
#16
JOURNAL ARTICLE
Guolin Ye, Peixian Chen, Xiangwei Liu, Tiancheng He, Xavier Pivot, Ruilin Pan, Dan Zhou, Lewei Zhu, Kun Zhang, Wei Li, Shuqing Yang, Jiawei Lin, Gengxi Cai, Huiqi Huang
BACKGROUND: The effectiveness and safety of pyrotinib have been substantiated in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC). However, the role of pyrotinib as a single HER2 blockade in neoadjuvant setting among BC patients has not been studied. The objective of this study was to evaluate the efficacy and tolerability of pyrotinib plus taxanes as a novel neoadjuvant regimen in patients with HER2-positive early or locally advanced BC. METHODS: In this single-arm exploratory phase II trial, patients with treatment-naïve HER2-positive BC (stage IIA-IIIC) received pyrotinib 400 mg once daily and taxanes [docetaxel 75 mg/m2 or nanoparticle albumin-bound (nab)-paclitaxel 260 mg/m2 every 3 weeks, or paclitaxel 80 mg/m2 weekly] for a total of four 21-day cycles before surgery...
March 27, 2024: Gland Surgery
https://read.qxmd.com/read/38550295/prolonged-cancer-control-with-adagrasib-in-patients-with-metastatic-kras-g12c-mutated-nsclc-after-sotorasib-induced-hepatotoxicity-a-case-report
#17
Natalie Stratton, Jonathan Thompson
Both sotorasib and adagrasib are approved for use in metastatic KRAS G12C -mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered adverse effect of both agents, and little data exists about the safety of sequential use of these agents when hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced a prolonged cancer response...
April 2024: JTO clinical and research reports
https://read.qxmd.com/read/38543254/new-mos-2-tegafur-containing-pharmaceutical-formulations-for-selective-led-based-skin-cancer-photo-chemotherapy
#18
JOURNAL ARTICLE
Miguel T Campos, Filipa A L S Silva, José Ramiro Fernandes, Susana G Santos, Fernão D Magalhães, Maria J Oliveira, Artur M Pinto
Non-melanoma skin cancer (NMSC) is one of the most common types of cancer worldwide. Despite the low mortality rate, rising incidence and recurrence rates are a burden on healthcare systems. Standard treatments such as chemotherapy, radiotherapy, and surgery are either invasive or toxic to healthy tissues; therefore, new, alternative, selective treatments are needed. In this work, a combined photothermal and chemotherapeutic approach is proposed. MoS2 was used as photothermal agent. It was prepared by a liquid-phase exfoliation and intercalation method using polyvinylpyrrolidone (PVP), followed by recirculation through a custom-built high-power ultrasonication probe...
March 4, 2024: Pharmaceutics
https://read.qxmd.com/read/38542413/onco-hypertension-a-continuously-developing-field-between-cancer-and-hypertension
#19
REVIEW
Stefan Totolici, Ana-Maria Vrabie, Elisabeta Badila, Emma Weiss
The prognosis of cancer patients has greatly improved in the last years, owing to the development of novel chemotherapeutic agents. However, this progress comes with an increasing occurrence of cardiovascular adverse reactions. A serious side effect is arterial hypertension (HT), which is the most frequent comorbidity encountered in cancer patients, influencing the outcomes in cancer survivors. Even though secondary HT related to specific chemotherapeutic agents, such as vascular endothelial growth factor inhibitors, is usually mild and reversible, in rare instances it can be severe, leading to discontinuation of chemotherapy...
March 19, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38527844/-blastic-plasmacytoid-dendritic-cell-tumor-treated-with-dvt-regimen-a-case-report-and-literature-review
#20
JOURNAL ARTICLE
J Shi, N Xu, Y Niu, S X Jia, C M Yang, M Y Fang
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy, there is no standard treatment and the prognosis is very poor. Affiliated Zhongshan Hospital of Dalian University report a case of 85-year-old BPDCN male patient treated with DVT regimen (decitabine combined with Venetoclax and thalidomide) and achieved complete remission. The patient with skin nodules and the pathology diagnosed BPDCN, the next generation sequencing of skin nodules showed mutations of IDH2 and ASXL1...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
keyword
keyword
29463
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.